| Immunocompetent cell functions in Ph(+) acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment. | |
| | |
MedLine Citation:
|
PMID: 21240485 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Imatinib mesylate (Imatinib) is a potent inhibitor of defined tyrosine kinases and is effectively used for the treatment of malignancies characterized by the constitutive activation of these tyrosine kinases, such as Philadelphia chromosome-positive (Ph(+)) leukemias and gastrointestinal stromal tumors. Suppressive as well as stimulating effects of this drug on T lymphocytes or dendritic cells (DC), which play a major role in immune tumor surveillance, have been reported. For this reason, we questioned whether Imatinib could also affect the phenotypic and functional properties of these subpopulations in Ph(+) acute lymphoblastic leukemia (ALL) patients on prolonged Imatinib maintenance treatment. Circulating T lymphocytes and NK cells from Imatinib-treated Ph(+) ALL patients showed a subset distribution comparable to that of healthy donors. In addition, T-cell immunomodulant cytokine production (IFN-γ, TNF-α) and proliferative responses were not impaired. A normal monocyte-derived DC differentiation and apoptotic body loading capacity was also observed in the majority of Imatinib-treated patients. In contrast, an impairment in the DC intracellular production of IL-12 was recorded, although this was not observed when normal DC were exposed in vitro to Imatinib. Finally, in vivo Imatinib treatment did not affect the T-lymphocyte proliferation and IFN-γ production induced by leukemic apoptotic body-loaded DC, underling the potential capability of these cells to generate a specific immune response against tumoral antigens. Taken together, these findings provide evidence that immunotherapeutic approaches aimed at controlling residual disease in Ph(+) ALL patients in hematologic remission are not jeopardized by the long-term administration of Imatinib. |
| | |
Authors:
|
Roberta Maggio; Nadia Peragine; Maria Stefania De Propris; Antonella Vitale; Loredana Elia; Elisabetta Calabrese; Irene Della Starza; Stefania Intoppa; Maria Laura Milani; Anna Guarini; Robin Foà |
Related Documents
:
|
15888915 - The proteasome: a central regulator of inflammation and macrophage function. 14712225 - The tumor suppressor p16(ink4a) gene is a regulator of apoptosis induced by ultraviolet... 11309365 - Inducible expression of mutant alpha-synuclein decreases proteasome activity and increa... 18931595 - Simultaneous inhibition of the constitutively activated nuclear factor kappab and of th... 7757525 - The complement system in trauma-related and ischemic tissue damage: a brief review. 19016445 - The isolation and characterization of murine macrophages. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-1-15 |
Journal Detail:
|
Title: Cancer immunology, immunotherapy : CII Volume: - ISSN: 1432-0851 ISO Abbreviation: - Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-1-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8605732 Medline TA: Cancer Immunol Immunother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University of Rome, Via Benevento 6, 00161, Rome, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Suppression of T-cell responses by tumor metabolites.
Next Document: Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologo...